Arcadia Biosciences Inc (RKDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcadia Biosciences Inc (RKDA) has a cash flow conversion efficiency ratio of -0.208x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-861.00K) by net assets ($4.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Arcadia Biosciences Inc (RKDA) total market value for the company's overall valuation and market capitalisation.
Arcadia Biosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Arcadia Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arcadia Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcadia Biosciences Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Arcadia Biosciences Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arcandor AG
DU:ARO
|
N/A |
|
Flowtech Fluidpower plc
LSE:FLO
|
-0.022x |
|
PCI-PAL PLC
LSE:PCIP
|
-0.753x |
|
Kovo Healthtech Corp
V:KOVO
|
0.032x |
|
Ondine Biomedical Inc
LSE:OBI
|
-3.853x |
|
Oriental Rise Holdings Limited Ordinary Shares
NASDAQ:ORIS
|
0.012x |
|
Jersey Electricity plc
LSE:JEL
|
0.039x |
|
Upland Resources Ltd
LSE:UPL
|
-0.179x |
Annual Cash Flow Conversion Efficiency for Arcadia Biosciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Arcadia Biosciences Inc from 2012 to 2025. View RKDA live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.14 Million | $-4.74 Million | -1.145x | +26.01% |
| 2024-12-31 | $6.22 Million | $-9.63 Million | -1.547x | -28.49% |
| 2023-12-31 | $12.70 Million | $-15.29 Million | -1.204x | -80.03% |
| 2022-12-31 | $20.90 Million | $-13.98 Million | -0.669x | +19.35% |
| 2021-12-31 | $31.20 Million | $-25.87 Million | -0.829x | +21.65% |
| 2020-12-31 | $28.55 Million | $-30.22 Million | -1.058x | +48.76% |
| 2019-12-31 | $8.33 Million | $-17.20 Million | -2.066x | -94.19% |
| 2018-12-31 | $12.81 Million | $-13.63 Million | -1.064x | +39.01% |
| 2017-12-31 | $8.01 Million | $-13.96 Million | -1.744x | -127.00% |
| 2016-12-31 | $22.20 Million | $-17.05 Million | -0.768x | -104.55% |
| 2015-12-31 | $40.23 Million | $-15.11 Million | -0.376x | -104.79% |
| 2014-12-31 | $-1.89 Million | $-14.79 Million | 7.845x | +1292.38% |
| 2013-12-31 | $-17.30 Million | $-9.74 Million | 0.563x | -66.60% |
| 2012-12-31 | $-5.68 Million | $-9.59 Million | 1.687x | -- |
About Arcadia Biosciences Inc
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief,… Read more